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Abstract
Background: Down syndrome (DS) is one of the most common chromosomal abnormalities among newborns. In
recent years advances in perinatal and neonatal care have improved chance of survival for the children with DS. The
objective of this Registry-Based study was to get more accurate data of DS prevalence with evaluation of antenatal
screening, neonatal and maternal features among total births in Croatia from 2009 to 2012.
Methods: We used retrospectively collected data for DS newborns from the medical birth database and perinatal
mortality database for the period of 2009–2012. Differences between DS and the referent population for each year in
quantitative measures were assessed with the independent t-test. Other differences in nominal and categorical values
were analyzed with the chi-square test.
Results: The total prevalence for DS in the period of 2009–2012 was 7.01 per 10,000 births, while the live-birth prevalence
was 6.49 per 10,000 births. The significant differences (p < 0.05) between the DS and reference populations for each year
were noticed for birth weight and length, gestational age, mother age, Apgar score of ≥6 after 5 min and breastfeeding.
Among newborns with DS, there were 64 (53.33 %) males and 56 (46.67 %) females versus 88,587 (51.76 %) males and
82,553 (48.23 %) females in the reference population. In the DS group compared to the reference population the mean
birth weight was 2845 grams versus 3467 grams in males and 2834 grams versus 3329 grams in females, respectively,
with a mean birth length of 47 cm versus 50 cm for both genders. The mean gestational age of the DS births
was 37 weeks and the mean age of the mothers was 32.6 years, versus 39 weeks and 29.1 years, respectively, in
the reference population. Only 68.3 % of children with DS were breastfed from birth, compared with 94.72 % of
children in the reference population.
Conclusions: The significant differences for neonatal and maternal features between DS and the referent population
were found similar to other studies. The total prevalence of DS in Croatia in the period of 2009–2012 was lower than
the previously estimated prevalence based on EUROCAT data. The establishment of a new national registry of congenital
malformations covering 99 % of all births in Croatia is necessary to improve the health and prosperity of children,
adolescents and adults with DS in Croatia.
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Background
Down syndrome (DS) is one of the most common
chromosomal abnormalities among newborns. DS re-
mains the most easily recognized condition and is associ-
ated with increased risk for cardiologic, endocrinologic,
hematologic and respiratory diseases. In recent years,
advances in perinatal and neonatal care have improved
the chances of survival in children with DS [1].
EUROCAT (European Surveillance of Congenital
Anomalies) is the principal source of information on the
epidemiology of congenital anomalies in Europe. It
currently surveys more than 1.7 million births per year,
covered by 43 registries in 23 countries [2].
In Europe, the total prevalence of DS is 22.0 per
10,000 births (11.2 per 10,000 live births) while the esti-
mated prevalence in Croatia is 12.35 per 10,000 births
(10.54 per 10,000 live births) [3, 4].
In Croatia, the registry that provides data for EUROCAT
is population-based, covering only 20.8 % of total births.
The registry covers northwestern Croatia in only urban
areas, two at the seaside (Pula, Rijeka) and another two
from continental areas (Varaždin, Koprivnica). In order to
get more accurate data regarding DS prevalence and peri-
natal mortality at the national level, as well as on the neo-
natal and maternal features of DS newborns, the total
births from 2009 to 2012 in Croatia were evaluated. The
medical birth database used in this study covers all births
at health institutions and includes all mothers and new-
borns with pathological conditions.
Methods
The data for this study were obtained from all health in-
stitutions for the period of 2009–2012. Data were proc-
essed at the Croatian National Institute of Public Health.
In Croatia, new birth certificates and perinatal death cer-
tificates have been introduced in routine health statistics
since 2000 in accordance with World Health Organisation
(WHO) recommendations, by using features from the Ob-
stetrical Quality Indicators and Data collection (OBSQID)
basic information sheet for the recording of births [5].
Perinatal deaths have been collected through perinatal
death certificates and coded according to the International
Classification of Diseases (ICD-10 revision) [6]. The birth
form includes a significant number of core and recom-
mended EURO-PERISTAT indicators, proposed by the
PERISTAT scientific committee. The mother’s and the
newborn’s pathologic conditions are recorded according
to ICD-10 revision codes [6]. In the present study, all re-
cords with ICD-10 codes were included (Q90: trisomy 21;
Q90.0: meiotic nondisjunction of chromosome 21; Q90.1:
mosaic Down syndrome; Q90.2: translocations involving
chromosome 21; Q90.9: Down syndrome, unspecified).
Comparisons between DS and a reference population
were done for timing of the first antenatal visit and
ultrasound examinations during pregnancy, birth weight
and length, gestational age, maternal age at delivery, Apgar
score of ≥6 after 5 min, breastfeeding after birth, path-
ology/complications in the newborn, educational level of
the mother, smoking, and consumption of alcohol or psy-
choactive drugs during pregnancy.
Differences between DS and the reference population
for each year in quantitative measures (birth weight,
birth length, gestational age and mother age) were
assessed with the independent t-test. Other differences
in nominal and categorical values, including differences
in total prevalence of DS per 10,000 births, were ana-
lyzed with the chi-square test. All p-values below 0.05
were considered significant. The StatsDirectversion
3.0.86 statistical software was used in all statistical pro-
cedures [7].
Results
In the period from 2009 to 2012, there were 171,140 total
births in Croatia. Among them, a total of 120 children
were born with DS, confirmed by chromosomal analysis.
The major chromosomal aberrations were trisomy 21
(Q90, Q90.9) in 76.6 % (n = 92) of the DS newborns and
meiotic nondisjunction of chromosome 21 (Q90.0) in
20.8 % (n = 25), while the remaining cases were caused by
mosaicism-mitotic nondisjunction (Q90.1).
Figure 1 shows the total and live-birth prevalence for
the observed period. The DS prevalence ranged from
4.38 to 10.06 per 10,000 births. A similar trend was no-
ticed for live-birth prevalence. The total prevalence in
this period was 7.01 per 10,000 births, while the live-
birth rate was 6.49 per 10,000 births.
Fourteen perinatal deaths (11.7 % of those born with
DS) were recorded in the period of 2009–2012. In this
period, the perinatal mortality rate for DS was 1,203.8
per 10,000 total births and for the reference population
was 68.4 per 10,000 total births, indicating at least a 17-
times higher perinatal mortality for DS compared to the
reference population (Table 1). Average fetal mortality
caused by DS was 709.25 per 10,000 total births, while
early neonatal mortality was 528 per 10,000 live births.
For the reference population, fetal and neonatal mortal-
ity was also 15–20 times lower at 42.1 and 25.8,
respectively.
Among newborns with DS, there were 64 (53.33 %)
males and 56 (46.67 %) females versus 88,587 (51.76 %)
males and 82,553 (48.23 %) females in the reference
population. In the DS group compared to the reference
population, the mean birth weight was 2845 grams ver-
sus 3467 grams in males and 2834 grams versus 3329
grams in females, respectively, with a mean birth length
of 47 cm versus 50 cm for both genders. The mean ges-
tational age of the DS births was 37 weeks and the mean
age of the mothers was 32.6 years, versus 39 weeks and
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29.1 years, respectively, in the reference population. Of
the DS births, there were 80 (66.7 %) pregnancies in
women aged ≥35 years. Only 68.3 % of children with DS
were breastfed from birth, compared with 94.72 % of
children in the reference population. Additionally,
significant differences (p < 0.05) between the DS and
reference populations for each year were noticed for
birth weight and length, gestational age, mother age,
Apgar score of ≥6 after 5 min and breastfeeding, while
there were no significant differences in parity (Table 1).
In 7 of the DS newborns, there were one or more add-
itional structural anomalies (Table 2). In 6 (5 %) of the DS
newborns, congenital heart defects (CHDs) were detected,
the most common being atrial septal defects (n = 3, 2.5 %),
followed by one newborn with a ventricular septal defect,
an atrioventricular septal defect and persistent ductus
Botalli. Also, in one newborn, anomalies of the urinary
system were detected. Other additional conditions in-
cluded 8 % (n = 10) of newborns with perinatal asphyxia,
0.8 % (n = 1) with thrombocytopenia, and 0.8 % (n = 1)
with leukemia.
Unfortunately, gestational age at first antenatal visit
was available only for 85 (70.8 %) of the children with
DS. Among them, in 79 cases of DS, the first antenatal
visit occurred in the first 14 weeks of gestation, which
meets the recommendations of the National Health Care
Program. Similarly, the first ultrasound examination
should be performed by 14 weeks of gestation, and our
data point out that the first ultrasound examination was
mainly done at the same time as the first antenatal visit.
In addition, anomaly-scanning ultrasounds were re-
corded for 46 children with DS. The Croatian National
Health Care Program recommends structural-anomaly
scanning at 18–22 weeks of gestation, which was per-
formed only in 38.3 % of the DS pregnancies.
Furthermore, the collected social features did not
show obvious risk behaviours in the mothers. For ex-
ample, of the total of 120 mothers, 91.7 % declared
themselves non-smokers and 95 % denied using alcohol
or psychoactive drugs during pregnancy. Also, there
were no similarities in the mothers’ levels of education.
According to available data, most had a secondary-
school education followed by college/university degree,
and three had only a primary-school education.
Discussion
Congenital anomalies, including DS, present an import-
ant public health issue since the surviving children have
special medical, social and educational needs. National
prenatal screening programs for DS and clinical guide-
lines for the further care of DS newborns should exist.
To create an efficient strategy, population-based data are
necessary. The Croatian registry of congenital anomalies
was established in 1983 and is limited to the northwest
of Croatia, part of central Croatia and part of the Croatian
coast (Primorje). This registry covers only 20.8 % of all
births and provides data about DC prevalence for EURO-
CAT. In order to get more reliable data for our study, the
prevalence and neonatal characteristics of children with
DS were based on total births at health institutions, cover-
ing 99 % of all births in Croatia. In this study, for example,
51.7 % of all newborns with DS were born in three large
counties that are not included in the Croatian registry of
congenital anomalies [8]. The total prevalence of DS in
Croatia in the period of 2009–2012 (7.01 per 10,000
births) was lower than the previously estimated prevalence
based on EUROCAT data [4]. In the period of 2008–2012,
the total prevalence, including terminated pregnancy for
fetal anomaly (TOPFA), live births and fetal deaths ob-
tained from EUROCAT were12.96, 8.93 and 8.90 per
10,000, respectively. According to EUROCAT, the total
prevalence in Europe was also much higher (22 per 10,000
births) [3]. There are large differences in DS prevalence
rates (5.99–43.03), which depend on sociocultural vari-
ables and abortion-legislation practices among EU coun-
tries. In the period of 2008–2012, TOPFA was performed
in 52.3 % of cases of prenatal DS detection (7,335 of a total
of 14,036 DS cases). In countries in which abortion is
Fig. 1 Total and live birth prevalence of DS per 10 000 births for period from 2009 to 2012 in Croatia
Glivetic et al. Italian Journal of Pediatrics  (2015) 41:81 Page 3 of 7
Table 1 Characteristic of children with Down syndrome (DS) and the reference population (REF)
2009. 2010. 2011. 2012.
DS REF DS REF DS REF DS REF
N = 33 N = 44673 N = 19 N = 43400 N = 26 N = 41306 N = 42 N = 41761
Birth weight (g, mean) 2906.7a 3409.8 2954.2a 3428.6 2954.2a 3389.4 2763.2a 3396.7
Birth length (cm, mean) 47.4a 50.2 46.1a 50.3 47.5a 50.1 46.9a 50.1
Gestational age (weeks, mean)b 36.7a 39.1 36.7a 39.2 37.8a 39.0 37.0a 39.0
Apgar ≥ 6 after 5 minb 22 (66.7 %)a 39694 (99.2 %) 12 (63.1 %)a 37728 (98.9 %) 20 (76.9 %)a 36079 (99.0 %) 30 (71.4 %)a 36859 (99.3 %)
Intervention on delivery 6 (18.2 %) 8913 (19.9 %) 7 (36.8 %) 9224 (21.3 %) 7 (26.9 %) 7213 (17.5 %) 19 (45.2 %) 8845 (21.2 %)
Parity 1 6 (18.2 %) 15002 (33.6 %) 8 (42.1 %) 14776 (34.0 %) 8 (30.8 %) 14083 (34.1 %) 12 (28.6 %) 14359 (34.4 %)
Parity 2 6 (18.2 %) 5643 (12.6 %) 1 (5.3 %) 5289 (12.2 %) 5 (19.2 %) 5015 (12.1 %) 5 (11.9 %) 5116 (12.3 %)
Parity 3 3 (9.1 %) 1597 (3.6 %) 1 (5.3 %) 1525 (3.5 %) 3 (11.6 %) 1469 (3.6 %) 3 (7.1 %) 1483 (3.6 %))
Parity ≥4 3 (9.1 %) 1017 (2.3 %) 0 (0.0 %) 1044 (2.4 %) 1 (3.8 %) 1015 (2.5 %) 1 (2.4 %) 1024 (2.5 %)
Parity 0 15 (45.4 %) 21414 (47.9 %) 9 (47.4 %) 20766 (47.8 %) 9 (34.6 %) 19724 (47.8 %) 21 (50.0 %) 19779 (47.4 %)
Mother age (years, mean) 32.7a 29.0 31.8a 28.2 32.0a 30.0 33.2a 29.2
Breast feeding 21 (63.6 %)a 42676 (95.5 %) 11 (57.9 %)a 40812 (94.0 %) 19 (73.1 %)a 39413 (95.4 %) 31 (73.80 %)a 40268 (96.4 %)
Perinatal mortality (on 10000) 5 (1515.2) 343 (76.8) 3 (1578.9) 323 (74.4) 2 (769.2) 268 (64.9) 4 (952.4) 240 (57.5)
Fetal mortality (on 10000) 4 (1212.1) 191 (42.7) 1 (526.3) 210 (48.4) 1 (384.6) 158 (38.3) 3 (714.3) 162 (38.8)
Early neonatal mortality (on 10000 newborns) 1 (344.8) 152 (34.2) 2 (1111.1) 111 (25.7) 1 (400.0) 102 (24.8) 1 (256.4) 77 (18.5)
aSignificant differences (P < 0.05) between DS regarding referent population for each year (birth weight, birth length, gestational age and mother age were assessed with independent t-test; other differences with
chi-square test)
bFor Apgar scoring total N for referent population were 40022 (2009), 38118 (2010), 36444 (2011) and 37119 (2012)
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illegal, such as Ireland and Malta, the DS prevalence is
higher, varying from 20 to 34 per 10,000 births [4]. In con-
trast, the DS prevalence in France is quite low (7.5 per
10,000), which is probably due to the high percentage
(77 %) of DS pregnancy terminations [9]. In Croatia,
TOPFA is legal until 22 weeks of gestation. However, we
do not have information on prenatally detected DS, which
could result in pregnancy termination and reduced overall
prevalence of DS. After 22 weeks of gestation, it is possible
to perform TOPFA outside of Croatia in countries with
less-restrictive abortion legislation. Also, TOPFA data are
not part of routine health statistics; only data about legally
induced abortions, spontaneous abortions and pregnancy
termination for all fetal anomalies are collected, which
does not allow us to make conclusions about pregnancy
terminations due to DS. Furthermore, it is important to
emphasize that birth records from routine health statistics
could be missing data about newborns’ pathologic condi-
tions, which does not allow complete insight into DS
prevalence.
EUROCAT has recently analyzed trends in DS prevalence
for the period from 1990 to 2009, during which an increas-
ing DS prevalence was noticed. The proportion of births in
Europe in the population of mothers aged ≥35 years in-
creased from 13 % in 1990 to 19 % in 2009, which is prob-
ably the reason for the increased total prevalence of DS
over time [3]. In our study, we found a proportion of
33.3 % of mothers aged ≥35 years who delivered newborns
with DS in Croatia. This is very similar to other European
countries [3, 9, 10].
Since 1990, widening of and improvements in ante-
natal screening techniques have resulted in a relatively
stable live-birth prevalence in Europe over time [11, 12].
One of the other probable reasons for the stable live-
birth prevalence is the availability of prenatal care and
routine prenatal ultrasounds. In Croatia, in accordance
with national compulsory health insurance, a program of
health care measures is recommended. The program in-
cludes one general and gynaecologic health examination,
with two pregnancy controls in the first trimester, three
pregnancy controls in the second trimester, and four
pregnancy controls in the third trimester of pregnancy.
In pregnancies with complications, the number of visits
and diagnostic procedures depends on specialist assess-
ments. In the framework of the program, the national
recommendation is to perform three ultrasound scans
during a normal pregnancy. The first scan is at 10–14
gestational weeks, followed by routine structural-
anomaly scanning at 18–23 weeks, with the last scan at
34–37 weeks. Since 2006, first-trimester screening with
biochemical markers and nuchal translucency measure-
ments have been also introduced as optional. In the
available records, 92.94 % of DS pregnancies had the
first antenatal visit in the first 14 weeks of gestation,
which meets the recommendations of the program. In
addition, the first ultrasound examination was usually
done at the same time as the first antenatal visit. Ac-
cording to a recent report by the Croatian Institute of
Public Health, more than 70 % of pregnant women had
first-trimester ultrasound screening after 12 weeks of
gestation [8]. In most European countries, country-wide
policies exist for routine anomaly-scanning ultrasounds.
Prenatal screening for DS in many countries has led to
large proportions of terminated pregnancies after pre-
natal diagnosis, which also influences the stable live-
birth prevalence over time [13]. For example, according
to the United Kingdom’s National Institute for Health
and Clinical Excellence (NICE) guidelines, pregnant
women in England and Wales should be offered screen-
ing for DS that should be performed by the end of the
first trimester, no later than at 20 weeks of gestation.
The combined test (biochemical markers and nuchal
translucency measurement) should be offered between
11 and 14 weeks of gestation, and no later than 20 weeks
[14]. According to EUROCAT, in 14 European countries,
66 % of DS cases are detected prenatally and 88 % of
those resulted in termination of pregnancy [15]. Detec-
tion of fetal anomalies on antenatal ultrasound offers
women and their partners information that may help
them to better prepare for the birth of their child, in-
cluding the option of delivery in a setting that permits
rapid access to specialists and to surgical or medical
care. In our study, we had no information about whether
the DS was prenatally or postnatally diagnosed, but in
38 % (46 cases of a total of 120 DS pregnancies), struc-
tural anomalies were reported on scanning. The absence
of a national screening policy is one of the reasons for
the lack of prenatal DS detection data in Croatia. In pre-
vious studies, it was observed that in countries with na-
tional screening policies, there are measurable impacts
on prenatal DS detection rates [13]. The detection rate
was higher in countries with primarily first-trimester
screening than in those with a mixed first- or second-
trimester screening policy. Also, countries with no na-
tional screening policies had significantly lower prenatal
detection rates for DS [13, 16].
In general, a higher level of education and having pre-
vious information on available screening tests, such as a
Table 2 Comorbidity of children with Down syndrom
Comorbidity of children with Down syndrom, n = 120
Congenital heart defects 5 % (n = 6)
Anomalies of the urinary system 0.8 % (n = 1)
Perinatal asphyxia 8 % (n = 10)
Trombocytopenia 0.8 % (n = 1)
Leukemia 0.8 % (n = 1)
Total 15 % (n = 19)
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nuchal translucency scan, biochemical tests and invasive
diagnostic testing by chorionic villus sampling or amnio-
centesis, influence a woman’s decisions about which
tests to perform [17]. Additionally, the knowledge level
about first-trimester DS screening has been positively as-
sociated with length of education [18]. In our study,
such conclusions could not be made. In the available
data, most of the mothers had a secondary-school edu-
cation followed by a college/university degree, and only
three had a primary-school education. However, provid-
ing information about available screening options to all
pregnant women at the local and national levels is a
technique for early and frequent prenatal diagnosis of
DS.
In our study, growth retardation in children with DS
was found, similar to other results [19, 20]. Previously
published charts for DS are based on American, Sicilian,
Swedish and Dutch populations, though the American
growth charts are most frequently used all over the
world [21–24]. Due to significant differences among
populations, it is important to have specific DS growth
charts for our population, which could be incorporated
into our future National Health Care Program for DS
children. Also, DS newborns have more frequent cases
of birth asphyxia (Apgar score of ≤6 after 5 min) which
corresponds to recent literature (2–8 %) [19, 25, 26].
Consequently, newborns with DS have more complica-
tions at birth.
Furthermore, 7 of the DS newborns in this study had
one or more additional structural anomalies, including 6
with CHD, corresponding to only 6 % of the children. In
recent studies, the prevalence of CHD in DS children
was much higher, ranging from 43 % to 57 % [25–28].
This low percentage of CHD could be partially explained
by the lower number of diagnosed CHDs in our mater-
nity wards. Several authors of studies of DS children
with major cardiac malformations found no clinical signs
in the first week of life, and therefore a normal neonatal
examination does not exclude CHD [29]. If possible, due
to these findings, newborns with DS should have echo-
cardiography performed during the first month of life.
Additionally, we had records from maternity wards,
without further follow-up during the newborn and infant
period, and those who were later diagnosed remain un-
recorded. A follow-up system should be incorporated
into national health policy to provide more accurate data
on structural anomalies. Because of the high incidence
of a significant CHD, early recognition can lead to the
successful early surgical treatment of CHD in children
with DS [30].
DS newborns are less frequently breastfed compared
with healthy children. The ability to breastfeed may be
influenced by a range of difficulties in the first few days
of life, often as a consequence of facial and other
anatomical structural abnormalities associated with DS.
Also, severe neonatal illness is common among DS new-
borns, leading to hospital admissions that are usually as-
sociated with medical interventions and mother-infant
separations that can interfere with breastfeeding. In our
study, we found similar results, with 68.3 % of children
with DS being breastfed from birth, compared with
94.72 % in the reference population. Our percentage of
breastfed DS children was higher than that reported in
some studies (43 %–48 %), suggesting that possible im-
provements, through the training of maternity-ward
health professionals and home-based support of breast-
feeding, could be made [19, 31].
Conclusion
Our study, for the first time, investigates the DS preva-
lence and neonatal characteristics among all newborns
in Croatia. The significant differences for neonatal and
maternal features between DS and the referent popula-
tion were found similar to other studies. The total preva-
lence of DS in Croatia in the period of 2009–2012 was
lower than the previously estimated prevalence based on
EUROCAT data. Additionally, we provided better insight
into some biological and social features that influence
perinatal outcomes, which could also be useful in devel-
oping preventive health care measures. Through this
study, the need to have a national screening policy for
fetal congenital anomalies was once again pointed out.
Such a policy should involve mandatory anomaly-
scanning for all pregnant women, which would increase
the opportunities to discover fetal congenital anomalies
and would help to prepare families to cope with them.
The establishment of a new national registry of congeni-
tal malformations covering 99 % of all births in Croatia
would be the best way to obtain the relevant informa-
tion, which is not always possible to find through rou-
tine health statistics. Without population-based data
about DS prevalence, preventive health care programs
will not be sufficiently effective. Also, a plan for age-
appropriate health care should be created to improve
the health and prosperity of children, adolescents and
adults with DS in Croatia.
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